Previously, CIPO had indicated that implementation was likely to occur in 2016 or 2017. Commissioner Bélisle's announcement pushes back implementation another year at least.

As we previously reported, Canada will be significantly changing its trademark law.

As we previously reported, Canada will be significantly changing its trademark law.

In an action commenced by Allergan against Apotex in respect of ulipristal (Allergan's FIBRISTAL) under the Patent Medicines (Notice of Compliance) Regulations (PMNOC ...

The Patented Medicine Prices Review Board (PMPRB) released its March 2018 NEWSletter (the first NEWSletter since July 2017). Highlights include:

Various legislative and regulatory changes are expected to bring both benefits and challenges to applicants in all industries by 2018.

As previously reported, on December 2, 2017, Canada's Governor-in-Council published proposed Regulations Amending the Patented Medicines Regulations for comment.

Effective June 24, 2016, amendments to the Patent Act and Trade-marks Act came into effect providing protection for confidential communications between clients and their patent agents and trademark agents..

The balance of Pfizer's motion to dismiss has been deferred to the trial in the liability phase of the proceeding.

Bill 96 was tabled today by the Government of Quebec proposing sweeping revisions to the Quebec's Charter of the French Language

In September 2017, the Patented Medicine Prices Review Board (PMPRB) decided that Alexion's SOLIRIS (eculizumab) was sold at an excessive price. In doing so, the Board departed from the Guidelines...

As previously reported, Amgen sought leave to appeal a decision of the Federal Court of Appeal (2020 FCA 188) affirming Justice Southcott's decision that the relevant claims of its filgrastim (NEUPOGEN)

As previously reported, the Federal Court of Appeal dismissed Apotex's appeal of a decision relating to macitentan (Janssen's OPSUMIT), which found that Apotex would induce infringement of Janssen's patent.

Eli Lilly seeks leave in olanzapine section 8 damages action.

As previously reported, the Federal Court of Appeal (FCA) dismissed Teva's appeal on the quantification of damages from infringement of Janssen's patent for levofloxacin (LEVAQUIN).

On June 30, the Supreme Court of Canada (SCC) delivered its highly anticipated decision, AstraZeneca v Apotex, 2017 SCC 36 relating to esomeprazole (NEXIUM).

REVLIMID (lenalidomide): Celgene v Taro.

On February 6, 2017, Mega Byte Information ("Mega Byte") was sentenced by the Court of Québec and fined $450,000 after pleading guilty to operating a deceptive telemarketing scheme...

We now have the first Undertaking involving alleged text message violations of Canada's Anti-Spam Legislation ("affectionately" known as CASL).

Therapeutic antibodies have grown to become an important product class within the biopharmaceutical market.